Peptide Proof — Evidence-Based Peptide Intelligence. Independent analysis. No paywall.
Here’s What Happened
Vedana Therapeutics launched from stealth on June 17, 2026 with a forty-six million dollars Series A round to develop antibody drugs targeting PACAP, which is a small protein that triggers migraines, a neuropeptide that drives migraine attacks through a pathway distinct from the well-established CGRP mechanism. The startup, backed by Westlake BioPartners and Canaan Partners, is led by the scientific and clinical teams that built the multi-billion-dollar CGRP migraine drug class at Alder Biopharmaceuticals, Labrys Biologics, and Amgen. With two programs — one targeting PACAP alone and a dual PACAP/CGRP bispecific — Vedana aims to enter human trials in 2027.
Context / Background
The CGRP inhibitor class — including Aimovig (erenumab), Ajovy (fremanezumab), and Emgality (galcanezumab) — transformed migraine prevention when it launched in 2018. These monoclonal antibodies block calcitonin gene-related peptide, a neuropeptide central to migraine pathophysiology. Combined, the class generates over seven billion dollars in annual revenue.
But a persistent problem remains: more than fifty percent of patients either do not respond to CGRP therapies or discontinue them within the first year. This treatment gap — estimated at 15–20 million patients worldwide — has sparked a race to identify the next migraine target. PACAP, a 38-amino-acid neuropeptide, has emerged as the leading candidate. It triggers vasodilation and neuroinflammation through PAC1, VPAC1, and VPAC2 receptors — a signaling cascade parallel to, but distinct from, CGRP.
The Data / The Deal
Company | Vedana Therapeutics — stealth until June 17, 2026 —.
Funding | forty-six million dollars Series A.
Lead Investors | Westlake BioPartners, Canaan Partners.
Target | PACAP neuropeptide — anti-PACAP monoclonal antibodies —.
Pipeline | 2 programs: anti-PACAP monotherapy + PACAP/CGRP bispecific.
Clinical Timeline | Human trials expected to start in 2027.
Key Competitor | Lundbeck — ALD1910, Phase 2, via two billion dollars Alder acquisition —.
Other Competitors | Mentari Therapeutics — reverse merger —, Slate Medicines — one hundred thirty million dollars raised —.
Leadership | CEO Anurag Agarwal; CSO Leon Garcia — ex-Alder PACAP lead —; CMO Ernesto Aycardi — ex-Teva Ajovy lead —.
Board | Rob Lenz — ex-Amgen Aimovig head —, Marcelo Bigal — ex-Labrys CMO —.
Expert Insight
Anti-pattern: Assuming PACAP will just be “CGRP 2.0.” Experienced teams know that the PACAP pathway has significant safety baggage. PACAP is broadly expressed — in the pituitary, adrenal medulla, and autonomic nervous system. Lundbeck’s ALD1910 showed signals of liver enzyme elevation and blood pressure effects in Phase 2, which is why the program hasn’t accelerated faster despite positive efficacy data. The winner in this space won’t be the company with the best PACAP binder — it will be the one that solves the therapeutic window problem. Vedana’s dual-targeting bispecific may help by allowing lower doses of each component.
Another underappreciated dimension: CGRP drugs succeeded partly because neurologists were desperate for migraine-specific options after decades of repurposed antidepressants and beta-blockers. PACAP drugs face a higher bar — they must demonstrate superiority over established, well-reimbursed CGRP therapies, not just novelty. Trial design matters enormously here; a head-to-head against CGRP standard-of-care is expensive but may be the only path to commercial relevance.
Further Reading
- GLP-1 Peptide Therapeutics: The Complete 2026 Landscape
- Peptide Drug Conjugates in the Clinic: 2026 Pipeline Review
- Neuropeptide Therapeutics Beyond CGRP: Emerging Targets and Strategies
[Natural sign-off — one sentence summary of why this matters.]
Last reviewed: June 2026. Peptide Proof Editorial Team. Source: BioPharma Dive
